In Depth 18 May 2020 Will Covid-19 Change the Face of Vaccine Development? …have not always had an easy ride. “Significant investment, in both time and money, is needed to advance a vaccine candidate to market,” Thomas Lingelbach, CEO of French vaccine developer… May 18, 2020 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 9 Apr 2025 Cystic fibrosis: is the next blockbuster a gene therapy? …this article, we will explore how gene therapy works, the biotechs progressing their genetic drug candidates, and why it might just be the breakthrough that people with cystic fibrosis have… April 9, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Mar 2024 7 oncolytic virus companies you should know about …it has developed an extensive library of isolated and engineered oncolytic vaccinia virus (a poxvirus similar to smallpox) immunotherapeutic product candidates. The oncolytic virus company’s most advanced candidate, Olvi-Vec (olvimulogene… March 14, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Dec 2023 Five companies racing to bring their NASH treatments toward the finish line …Drug Administration (FDA)-approved treatments for the disease, many NASH companies are currently attempting to bring their candidates toward approval. In this article, we take a look at five of the… December 21, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 23 Apr 2025 The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval …exclusive rights to the candidate in the field of multiple sclerosis worldwide and certain other autoimmune diseases outside of China. Biogen did not specify why it had dropped the candidate… April 23, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2018 Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results An antibody therapy for the blood cancer multiple myeloma achieved positive results at Phase III, decreasing the risk of the disease getting worse and patient death by 45% in a… October 31, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Mage Biologics created to develop oral antibody therapy for ulcerative colitis …(PFC) investment for TVM LSI II. Mage Biologics plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (mAb) bioengineered for optimal potency and tissue… July 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2017 Antibody Treatment for Obesity and Type 2 Diabetes enters Phase II Novartis is initiating Phase II trials with an antibody licensed from German biotech MorphoSys that tackles the obesity and diabetes epidemic. MorphoSys is a billion euro biotech that develops therapeutic… January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 WuXi Biologics and Toregem BioPharma to develop antibody for adentia treatment …Takahashi investigated the effects of a monoclonal antibody for USGA-1. His experiments with this antibody revealed that BMP/Wnt signaling was critical for determining the number of teeth in mice, and… October 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Watch: Antibody Analytics opens new health sciences center A new facility dedicated to the advancement of medical research and drug development opened its doors recently in Motherwell, Scotland, as part of a major expansion. Antibody Analytics, one of… June 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments ADC Therapeutics has received massive private funding to progress two of its lead candidates for cancer through clinical trials. ADC Therapeutics, based in Lausanne, Switzerland, specializes in developing antibody-drug conjugates… October 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2017 What are the Current Challenges in the Booming Field of ADCs? …carboxylic acids on an antibody. Another linker-related problem in ADC development is the drug-antibody ratio (DAR): it’s difficult to pin an exact number of toxins to an antibody and even… February 24, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email